Background: FGFR1 copy number gain (CNG) occurs in head and neck squamous cell cancers
FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers

STATEMENT OF TRANSLATIONAL RELEVANCE
FGFR1 has emerged as a therapeutic target in a number of human solid cancers including lung squamous cell carcinomas and breast cancers. Herein, we demonstrate that growth inhibition of HNSCC cell lines and patient-derived xenografts is statistically associated with FGFR1 mRNA and protein expression, but not copy number gain in HNSCC. Importantly, as a single biomarker, FGFR1 amplification greatly underestimates the potential prevalence of FGFR1-driven HNSCC and only partially overlaps with FGFR1 mRNA expression. Thus, a biomarker encompassing FGFR1 expression, either mRNA or protein, should be considered for more accurate and comprehensive enrollment of HNSCC patients to clinical trials with FGFR-specific tyrosine kinase inhibitors.
Research. 
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is a common and lethal cancer with a 40-50% 5-year survival rate (1) . The risk factors for HNSCC include tobacco and alcohol use, human papilloma virus (HPV) infection and inherited disorders such as Fanconi anemia (1) (2) (3) . With the exception of the anti-EGFR therapeutic cetuximab, HNSCC has evaded the modern advances of personalized medicine involving deployment of targeted therapeutics that block distinct driver oncogenes present in individual tumors. Recently, a wealth of genomic information has become available on HNSCC with the expectation that driver oncogenes susceptible to targeted therapies would be identified. In contrast to other solid tumors such as lung adenocarcinoma and melanoma where discrete subsets of these cancers are defined by actionable driver oncogenes, a similar picture in HNSCC has not emerged so far (4) (5) (6) (7) . Rather, sporadic mutations in RAS family members and PIK3CA were observed with the majority of tumors lacking an obvious driver oncogene (4).
The FGFR family of receptor tyrosine kinases (RTKs) is encoded by 4 distinct genes and are established as bona fide oncogenes in diverse human cancers through somatic mutation, gene rearrangements encoding activated fusion proteins, gene amplification and by ligand-dependent activation through paracrine and autocrine FGFs (8) (9) (10) (11) . Our group and others have reported FGFR1 amplification in HNSCC at a frequency of 15% (9, 12) , consistent with the frequency of FGFR1 amplification observed in lung squamous cell carcinomas (13, 14) . In fact, the association of FGFR1 amplification in lung cancer cell lines with sensitivity to FGFR-specific TKIs (13, 14) provides the rationale for ongoing trials of two FGFR inhibitors, NVP-BGJ398 (15) and AZD4547 (16) , in human cancers where FGFR1 amplification status as well as FGFR2 amplification and FGFR3 mutation serve as a biomarker for patient enrollment. BGJ398 is an orally bioavailable, small molecule pan FGFR kinase inhibitor, predominantly active on FGFR1-3 (17) . BGJ398 is currently being tested in ten clinical trials (Phase I and II), out of which three are on solid tumors (NCT01004224, NCT01928459, NCT02160041 positive HNSCC, invoking an oncogenic role for these FGFRs distinct from FGFR1 that is largely amplified in HPV negative HNSCC (6) .
Distinct from the aforementioned mechanisms of FGFR pathway activation, our previous study demonstrated a requirement for autocrine FGF2 in the growth of a subset of HNSCC cell lines (18) . It is noteworthy that ligand-mediated paracrine and autocrine activation mechanisms of FGFR cannot be detected by the genomic landscape projects, such as The Cancer Genome Project (TCGA), as no mutations or amplifications are required. In fact, increased expression levels of FGFs and FGFRs would be predicted to serve as markers of autocrine/paracrine FGFR activation. In this regard, the aims of our present study were to rigorously define the ability of FGFR1 amplification to predict FGFR inhibitor sensitivity in HNSCC cell lines and patient-derived xenografts (PDXs) relative to FGFR1 mRNA expression levels. In addition, we defined the prevalence of increased FGFR1 mRNA expression in primary HNSCC and determined the degree of overlap of a FGFR1 copy number gain (CNG) with increased mRNA expression. The findings support a view that FGFR1 mRNA expression may serve as the more accurate and comprehensive biomarker of FGFR1 dependent HNSCC.
METHODS
HNSCC patient cohort
The patient cohort was described in a previous publication (9) . In brief, we assessed 452 primary tumor tissues where 353 were measurable for both FGFR1 copy number by FISH and mRNA levels by in situ hybridization (see below). Sites of available primary tumor tissue origin were distributed as follows: hypopharynx (n=56), oropharynx (n=142), oral cavity (n=111), larynx (n=143). Clinico-pathological data was available for all patients. In a previous study, all patient samples were tested for p16 positivity. P16-positive cases were then further analyzed for HPV expression (9) . The study was approved by the institutional review board of the University Hospital of Bonn (#148/11).
mRNA in situ hybridization (ISH) assay
Research. The FGFR1 mRNA expression status of 452 primary HNSCC patients was examined using the RNA Scope technology for mRNA in situ hybridization (Advanced Cell Diagnostics, Hayward, CA). FGFR1 mRNA molecules were detected with single copy detection sensitivity. All tumor microarray (TMA) slides were digitized using a Zeiss MIRAX MIDI scanner. Staining intensity was evaluated by two independent observers (F.G., A.F.) and scored as described in the legend to Fig. S5 . In cases of discrepant results, samples were reassessed by an independent evaluator (S.P.) to obtain consensus.
HNSCC cell lines
The HNSCC cell lines in Tab 
HNSCC patient-derived xenograft (PDX) studies
The collection of 39 HNSCC PDX models (Tab. S1) developed and maintained at the University of Colorado Hospital and Anschutz Medical Campus in accordance with an approved protocol (COMIRB #08-0552) has been previously described (19) . For analysis of FGFR1 mRNA and gene copy number, a TMA was stained as described above. Studies involving propagation of the PDXs in female nu/nu mice and treatment of xenograft bearing mice with BGJ398 were approved by the Institutional Animal continued on treatment until signs of morbidity or maximal permitted tumor size at which point they were euthanized. 
Cell proliferation assay
Cell lines were plated at 100 to 500 cells per well in 96 well tissue culture plates and treated with NVP-BGJ398 (Novartis, Nuernberg, Germany) at various doses in triplicate (DMSO diluent, 0.01, 0.03, 0.1, 0.3, and 1.0 µM). Cells were fed with fresh medium containing drugs after 3 days and allowed to proliferate for a total of 7 days. Relative cell number was assessed using a CyQUANT Direct Cell Proliferation Assay (Invitrogen, Darmstadt, Germany) according to instructions provided by the manufacturer.
Clonogenic or anchorage-independent growth assays
To measure the effect of NVP-BGJ398 on single cell colony formation in a clonogenic assay, UMSCC1 and UMSCC25 cells were seeded at 200 cells/well in 6-well plates in full media. Twenty-four hours later, cells were treated with BGJ398 at various doses (DMSO, 0.01, 0.03, 0.1, 0.3, 1.0 µM) and allowed to grow for 10-14 days with feeding once a week. Wells were then rinsed with 1X PBS and stained with 0.5% crystal violet in 6% gluteraldehyde solution. For measurement of anchorageindependent growth of 584-A2 and SCC9 cell in soft agar, 20,000 cells were suspended in 1.5mL media and 0.35% noble agar and overlaid on base layers containing 1.5mL media and 0.5% noble agar in 6-well plates. Wells were fed once a week and allowed to grow for 14 to 21 days. Viable colonies were stained for 24 hrs with 250µL 1mg/mL nitroblue tetrazolium. Digital photographs of both clonogenic and soft agar wells were used to quantify total colony area by Metamorph imaging software.
Silencing of FGFR1 mRNA for testing growth dependency on FGFR1
HNSCC cell lines were transduced with a lentivirus encoding a shRNA targeting green fluorescent protein (GFP) as a negative control for RNAi or lentiviruses encoding two independent FGFR1-targeting shRNAs. The cells were selected for growth in puromycin-containing medium for 14 days and the viable cells were stained with crystal violet. The percent of clonogenic outgrowth relative to the GFP shRNA was determined by Metamorph quantification.
Immunoblot assays
Extracts were prepared as previously described (18) Technology) was performed as a loading control. FGFR1 protein levels detected with the C-terminal antibody were assessed from densitometry of the immunoblot and normalized to the α-subunit of NaKATPase; the resulting value for 584-A2 cells was designated as 1.0.
Real-time quantitative PCR assays.
Total RNA was purified from cells using RNeasy TM mini kits (QIAGEN, Valencia, CA) and aliquots (5 μg) were reverse transcribed in a 20 μl volume using random hexamers and MMLV reverse transcriptase. Aliquots (5 μl) of the reverse transcription reactions were submitted to PCR reactions with SYBR ® green Jumpstart Taq Readymix (Sigma-Aldrich, St. Louis, MO) using an I Cycle (BioRad, Hercules, CA). Primers used for FGF2, FGFR1-3 QPCR assays are as previously described (18).
Expression of the different mRNAs in samples was normalized to GAPDH mRNA levels measured by quantitative RT-PCR in replicate samples. Data are presented as "Relative Expression".
Ki-67 and cleaved caspase 3 staining.
Cytospins of 584-A2 HNSCC cells (~1x10 5 cells/slide) were generated with a Shandon Cytospin 4 centrifuge (Thermo Electron Corporation) and fixed with paraformaldehyde overnight. Subsequently, immunohistochemistry was performed using the Ventana Discovery automated immunostaining system (Ventana Medical Systems, Tuscon, AZ) and Ventana reagents. Antibodies used were rabbit monoclonal Ki67 (30-9; 1:100; Ventana Discovery, Roche, Mannheim, Germany) and rabbit polyclonal cleaved caspase 3 (1:100; DCS Innovative Diagnostic Systems).
RESULTS
FGFR1 expression and copy number status in HNSCC cell lines
We explored the relationship between FGFR1 CNG, FGFR1 mRNA and protein expression and the expression of FGFR1-3 and FGF2 mRNA in a panel of twelve HNSCC cell lines, all of which proved to
Research. be HPV-negative (Tab. 1). Among the cell lines, FGFR1 mRNA was exclusively expressed in CCL30, 584-A2 and SCC9 cells. Immunoblot analysis of cell extracts confirmed the mRNA measurement with FGFR1 protein expression restricted to these three cell lines (Fig. 1) . FGFRs are subject to extensive alternative mRNA splicing (see (8) (9) (10) (11) ) that results in the multiple polypeptides detected by the antibody. Note that the FGFR1 polypeptide expressed by CCL30 cells is not detected by an antibody directed against the C-terminus, but is detectable with an antibody directed against an epitope within the N-terminal region of the protein. FGFR1 copy number status was measured in the HNSCC cell lines by FISH (Fig. S1) The panel of HNSCC cell lines was tested for growth sensitivity with CyQUANT assays (Fig. 2A) or anchorage-independent/clonogenic growth assays (Fig. 2B) in the presence of increasing concentrations of the FGFR-specific TKI, BGJ398 (15) . The calculated IC 50 values are graphed in Fig.   2C and presented in Tab. 1. Combined, the data demonstrate high sensitivity of 584-A2, CCL30 and SCC9 cells to BGJ398 with IC 50 values less than 100 nM. As a confirmatory measurement, analysis of the Ki67 proliferation index also showed a dose dependent reduction in proliferative activity after 48 hours of BGJ398-treatment in 584-A2 cells (Fig. S2) . The remaining HNSCC cells we examined for growth inhibition exhibited IC 50 s that are greater than 500 nM, a concentration that is outside the therapeutic spectrum of BGJ398 for FGFRs (15, 17) . Increased levels of cleaved caspase 3 in BGJ398-treated 584-A2 cells is indicative of an increased apoptosis rate and suggests FGFR pathway addiction in this cell line (Fig. S2B) . In addition to inhibition of multiple measures of growth and apoptosis in 
target phospho-ERK1/2 in 584-A2, CCL30 and SCC9 cells in a dosage-dependent manner (Fig. S2C) . By contrast, there was no effect of BGJ398 on pERK levels in HN, UMSCC25 or UMSCC1 cells that lack FGFR1 expression (Fig. S2C) or on the pAKT status in any of these cell lines (data not shown).
The full panel of HNSCC cell lines ranking from the most to the least sensitivity to BGJ398 as determined by inhibition of cell proliferation is shown in Fig. 2C and reveals a correlation of TKI sensitivity with the expression of FGFR1 mRNA (p=0.04) and protein p=0.0002). While FGF2 mRNA expression was weakly associated (p=0.079) with the BGJ398 IC 50 values, FGFR2 and FGFR3 mRNA levels were not significantly associated and generally low in the BGJ398-sensitive cell lines (Tab. 1, Fig. S3 ). In addition, the FGFR1 GCN status did not associate with BGJ398 IC 50 values or with FGFR1 mRNA or protein expression (Tab. 1, Fig. S3 ). In fact, the only HNSCC cell line bearing FGFR1 CNG (HN) failed to express FGFR1 mRNA or protein and showed no sensitivity to BGJ398. In summary, analysis of a panel of twelve HNSCC cell lines reveals three cell lines that are BGJ398 sensitive and demonstrates an association with FGFR1 mRNA and protein expression, but not FGFR1 CNG. In conclusion, the predictive biomarker for FGFR1 TKI sensitivity in HNSCC is FGFR1 mRNA and protein expression.
To confirm FGFR1 dependency regarding treatment with BGJ398, the BGJ398-sensitive cells 584A2 and CCL30 as well as BGJ398-insensitive UMSCC8 cells were transduced with lentiviral vectors encoding two independent shRNAs targeting FGFR1. As shown in Fig. S4 , clonogenic growth of 584A2 and CCL30 cells was inhibited by FGFR1 shRNAs relative to the GFP control. This correlated with reduction of FGFR1 mRNA levels. UMSCC8 cells which lack FGFR1 expression ( Fig. 1) and are insensitive to BGJ398 (Fig. 2) were unaffected by transduction with shRNAs targeting FGFR1. Thus, the findings reveal that a subset of HNSCC cell lines highly express and are dependent on FGFR1 for growth as assessed by both molecular and pharmacological means. 
Partial overlap of FGFR1 mRNA expression with FGFR1 CNG in primary HNSCC
We employed in situ hybridization (ISH) for detection of FGFR1 mRNA in primary HNSCC specimens ( Fig. 3 and Fig. S5 ). Expression scores were binned into no expression (0), low expression (1-2) and medium/high expression (3-4). Overall, 29% (111/385 cases) displayed elevated levels (score 3-4), 56% (214/385) displayed a low expression pattern (1-2) and 16% (60/385) showed no FGFR1 mRNA transcripts (Fig. 4A) . Next, we correlated FGFR1 mRNA levels with FGFR1 status in 353 cases of formalin-fixed paraffin-embedded (FFPE) patient samples for which both FGFR1 mRNA and copy number status were available. Among the 63 FGFR1 amplified/polyploid cases (41 low level amplification, 13 high level amplification and 9 polyploid), 35% (22/63 cases) also displayed elevated levels of FGFR1 mRNA (score 3-4+), whereas 65% (41/63) of cases harbouring CNG expressed FGFR1 mRNA at low (0-2+) levels (Fig. 4A) . Furthermore, of the 290 patient samples without FGFR1 CNG, 31% (89/290) exhibited increased FGFR1 mRNA levels (3-4+), whereas 69% (201/290) of diploid/deleted cases had no or low FGFR1 mRNA levels (0-2) (Fig. 4A) . Staining patterns of specific tumors exhibiting FGFR1 mRNA and/or CNG are shown in Fig. 3 . To independently validate this modest degree of overlap between FGFR1 mRNA expression and CNG, we queried RNAseq and gene copy number data derived from 279 HNSCC tumors that are deposited in The Cancer Genome Atlas (TCGA) (Fig. 4B) . Using FGFR1 mRNA levels ≥ mean of the 279 tumors as the threshold for positivity, 34% (94/279) of tumors were positive for FGFR1 mRNA and 9% (24/279) showed FGFR1 CNG.
Among the tumors with FGFR1 CNG, 58% were also positive for FGFR1 mRNA (Fig. 4B) . Thus, the overall frequency of increased FGFR1 mRNA is similar in the University Hospital of Bonn cohort and TCGA tumor collection (29% and 34%, respectively) with degrees of overlap between mRNA positivity and CNG of 35% and 15%, respectively. While increased FGFR1 GCN has been observed to be enriched in HPV-negative HNSCC tumors (6), elevated FGFR1 mRNA expression was detected at similar frequencies in both HPV positive and negative cases (Fig. S6) .
FGFR1 mRNA as a predictive biomarker for BGJ398 sensitivity in a panel of HNSCC patientderived xenografts (PDXs).
To independently test the utility of FGFR1 mRNA and gene copy number status as predictive biomarkers of FGFR inhibitor response, a collection of 39 HNSCC PDXs was assayed for FGFR1 mRNA and gene copy number status (Tab. S1). Among these, 7/39 (18%) expressed FGFR1 mRNA at 3-4+; two PDX cases exhibiting 4+ mRNA staining were selected (CUHN015 and CUHN072). Only 1/39 PDXs (CUHN072) exhibited high-level FGFR1 CNG while CUHN015 showed a FGFR1/CEP8 signal ratio of 1.6. Importantly, RNAseq analysis of a subset of the PDX models revealed FGFR1 expression patterns that were in good agreement with the in situ hybridization-based assay (Tab. S1, p=0.0147).
As an FGFR1 mRNA and CNG negative control, CUHN036 was selected (ISH score = 0). All three cases are HPV-negative. FGFR1 protein levels were assessed by immunoblot analysis of tumor extracts (Fig. 5A) , revealing high FGFR1 protein levels in both of the mRNA positive tumors. CUHN015 and CUHN072 were propagated as flank xenografts in nu/nu mice and treated by daily gavage with BGJ398 (30 mg/kg) or with diluent control. CUHN015 xenografts exhibited significant growth inhibition with BGJ398 relative to diluent control-treated tumors (Fig. 5B) , demonstrating that a non-CNG HNSCC tumor can respond to an FGFR inhibitor. Surprisingly, and despite amplification and high expression of FGFR1, CUHN072 xenografts exhibited no significant response to BGJ398 (Fig. 5C) .
The CUHN072 tumors expressed FGF2 protein at levels equivalent to cultured 584-A2 cells (65.5 and 55.8 pg/μg protein, respectively), suggesting that the failure to respond to BGJ398 was not due to inadequate ligand expression. The mechanism for the intrinsic resistance of CUHN072 to BGJ398 is presently under further investigation and preliminary evidence supports strong activation of the MTOR pathway as a candidate explanation. Similar to our findings with FGFR1 mRNA and gene copy number status in HNSCC, FGFR1 protein levels showed no correlation to FGFR1 amplification status (12) . Others and we have also observed a lack of correlation between FGFR1 mRNA levels and gene copy number status in lung cancer (25-27).
Our findings suggest additional mechanisms regulate the transcription of FGFR1 beyond simple increases in gene copy number. Also, the discrepant prognostic associations assigned to FGFR1 amplification in lung squamous cancers (28, 29) and HNSCC (9) may, in fact, be linked to neighboring genes in the amplicon such as WHSC1L1. Moreover, alternative mRNA splicing may occur at exons encoding the extreme C-terminus of FGFR1 (see Fig. 1 ) similar to what has been described for FGFR2 (30) . To date, regulatory epigenetic mechanisms leading to FGFR1 mRNA and protein up-regulation are poorly defined and should be a subject of additional investigation.
Research. . 1, Fig. S3) . Thus, we propose that FGFR2 and FGFR3 play little or no role in driving growth of these cell lines and that the response of the cells to BGJ398 is therefore likely due to an inhibition of FGFR1 activity. FGF2 levels proved to be relatively high in TKIsensitive cells, pointing to an activation of FGFR1 through autocrine signaling as previously proposed.
The reduction of basal phospho-ERK levels in 584-A2, CCL30 and SCC9 cells is consistent with the proposed autocrine activity of FGF2 in these HNSCC cells as detected with TKIs and an FGF ligand trap (18) . The degree of co-expression of FGF2 and FGF9 with FGFR1 mRNA in TCGA HNSCC tumors (Fig. 4B) is consistent with this notion. It is noteworthy that the FGFR1 mRNA positive tumors likely represent a distinct subset from HNSCCs bearing FGFR2 or FGFR3 mutations (Fig. 4B) . The two FGFR2/3 mutation positive tumors within the FGFR1 mRNA positive subset do not express these genes at the mRNA level (data not shown). This observation is consistent with a recent study demonstrating that HNSCCs bearing FGFR2 and FGFR3 mutations largely represent HPV-positive tumors relative to FGFR1 CNG, a marker enriched in HPV-negative HNSCC (6) . In our previous study we also reported FGFR1 amplification and HPV-infection to occur mutually exclusive (11) . By contrast, in our present study, we observe increased FGFR1 mRNA levels being in HPV-positive as well as in HPV-negative tumor samples. Additionally, our analysis of HNSCC TCGA data indicates that FGFR1 mRNA positivity overlaps broadly with PIK3CA and TP53 mutations, suggesting that presence of these mutations will not exclude sensitivity to FGFR inhibitors.
Finally, this study provides important precedent for therapeutic advancement on an oncogene driver pathway that cannot be identified in human tumors through simple assessment of somatic mutation or gene amplification events. Our previous studies demonstrated the importance of autocrine FGF2 for the growth of both lung cancer and HNSCC cell lines (18, 31) . In fact, an autocrine role for FGFs in cancer is consistent with the long-established findings that specific FGF genes are transforming genomic integration sites for MMTV in murine breast cancer (32) . Thus, in addition to the documented role 
